In situ detection of matrix metalloproteinase-2 (MMP2) and the metalloproteinase inhibitor TIMP2 transcripts in human primary hepatocellular carcinoma and in liver metastasis

Journal of Hepatology

Volumn 26, Issue 3, 1997, Pages 593-605

  Musso, Orlando ^a   Théret, Nathalie ^a   Campion, Jean Pierre ^a   Turlin, Bruno ^a   Milani, Stefano ^b   Grappone, Cecilia ^b   Clément, Bruno ^a  

^a UNIVERSITÉ DE RENNES 1   (France)

^b NONE

Author keywords

hepatic stellate cells; hepatocellular carcinoma; human liver; matrix; metalloproteinase 2; metastasis; TIMP2

Indexed keywords

MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; MESSENGER RNA;

ARTICLE; CANCER INVASION; DNA SEQUENCE; ENDOTHELIUM CELL; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOLOGY; IN SITU HYBRIDIZATION; IN VITRO STUDY; LIVER CELL CARCINOMA; LIVER METASTASIS; PRIORITY JOURNAL;

EID: 0343051765     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(97)80425-4     Document Type: Article

References (45)

1. Stetler-Stevenson WG, Aznavoorian S, Liotta LA. Tumor-cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Biol. 9:1993;541-573.
2. Birkedal-Hansen H, Moore WGI, Bodden MK, Windsor LJ, Birkedal-Hansen B, De Carlo A, Engler JA. Matrix metalloproteinases: a review. Crit Rev Oral Biol Med. 4:1993;197-250.
3. Birkedal Hansen H. Proteolytic remodeling of extracellular matrix. Curr Opinion Cell Biol. 7:1995;728-735.
4. Imai K, Shikata H, Okada Y. Degradation of vitronectin by matrix metalloproteinases-1,-2,-3,-7 and -9. FEBS Lett. 369:1995;249-251.
5. Stetler-Stevenson WG, Krutzsch HC, Liotta LA. Tissue inhibitor of metalloproteinase (TIMP-2). A new member of the metalloproteinase inhibitor family. J Biol Chem. 264:1989;17374-17378.
6. Nakajima M, Morikawa K, Fabra A, Bucana C, Fidler IJ. Influence of organ environment on extracellular matrix degradative activity and metastasis of human colon carcinoma cells. J Natl Cancer Inst. 82:1990;1890-1898.
7. r 72,000) expression in human prostate: benign and malignant tissue. Cancer Res. 53:1993;878-883.
8. Davies B, Waxman J, Wasan H, Abel P, Williams G, Krausz T, Neal D, Thomas D, Hanby A, Balkwill F. Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion. Cancer Res. 53:1993;5365-5369.
9. Kusukawa J, Sassaguri Y, Shima I, Kameyama T, Morimatsu M. Expression of matrix metalloproteinase-2 related to lymph node metastasis of oral squamous cell carcinoma. A clinicopathologic study. Am J Clin Pathol. 99:1993;18-23.
10. Shima I, Sasaguri Y, Kusukawa J, Yamana H, Fujita H, Kakegawa Y, Morimatsu M. Production of matrix metalloproteinase-2 and metalloproteinase-3 related to malignant behavior of esophageal carcinoma. A clinicopathologic study. Cancer. 70:1992;2747-2753.
11. Testa J. Loss of the metastatic phenotype by a human epidermoid carcinoma cell line HEp-3 is accompanied by increased expression of tissue inhibitor of metalloproteinase 2. Cancer Res. 52:1992;5597-5603.
12. DeClerck Y, Perez N, Shimada H, Boone T, Landley K, Taylor S. Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res. 52:1992;701-708.
13. Nuovo GJ, MacConnell PB, Simsir A, Valea F, French D. Correlation of the in situ detection of polymerase chain reaction-amplified metalloproteinase complementary DNAs and their inhibitors with prognosis in cervical carcinoma. Cancer Res. 55:1995;267-275.
14. Polette M, Clavel C, Birembaut P, DeClerck YA. Localization by in situ hybridization of mRNAs encoding stromelysin 3 and tissue inhibitors of metalloproteinases TIMP-1 and TIMP-2 in human head and neck cancers. Pathol Res Pract. 189:1993;1052-1057.
15. Visscher DW, Höyhtyä M, Ottosen SK, Liang CM, Sarkar F, Crissman JD, Fridman R. Enhanced expression of tissue inhibitor of metalloproteinase-2 (TIMP-2) in the stroma of breast carcinomas correlates with tumor recurrence. Int J Cancer. 59:1994;339-344.
16. Monteagudo C, Merino MJ, San-Juan J, Liotta L, Stetler-Stevenson WG. Immunohistochemical distribution of type IV collagenase in normal, benign and malignant breast tissue. Am J Pathol. 136:1990;585-592.
17. Soini Y, Pääkkö P, Autio-Harmainen H. Genes of lamininβ1 chain, α1 (IV) collagen, and 72-dD type IV collagenase are mainly expressed by the stromal cells of lung carcinomas. Am J Pathol. 142:1993;1622-1630.
18. Boarg AH, Young ID. Increased expression of the 72-dK Type IV collagenase in prostatic adenocarcinoma. Demonstration by immunohistochemistry and in situ hybridization. Am J Pathol. 144:1994;585-591.
19. Poulsom R, Pignatelli M, Stetler-Stevenson WG, Liotta LA, Wright PA, Jeffrey RE, Longcroft JM, Rogers L, Stamp GWH. Stromal expression of 72 kda type IV collagenase (MMP-2) and TIMP-2 mRNAs in colorectal neoplasia. Am J Pathol. 141:1992;389-396.
20. Poulsom R, Hanby AM, Pignatelli M, Jeffrey RE, Longcroft JM, Rogers L, Stamp GWH. Expression of gelatinase A and TIMP2 mRNAs in desmoplastic fibroblasts in both mammary carcinomas and basal cell carcinomas of the skin. J Clin Pathol. 46:1993;429-436.
21. Gress TM, Müller-Pillasch F, Lerch MM, Freiss H, Büchler M, Adler G. Expression and in situ localization of genes coding for extracellular matrix proteins and extracellular matrix degrading proteases in pancreatic cancer. Int J Cancer. 62:1995;407-413.
22. Nigam AK, Pignatelli M, Boulos PB. Current concepts in metastasis. Gut. 35:1994;996-1000.
23. Milani S, Herbst H, Shuppan D, Grappone C, Pelligrini G, Pinzani M, Casini A, Calabro A, Ciancio G, Stefanini F, Burroughs AK, Surrenti C. Differential expression of matrix-metalloproteinase-1 and -2 genes in normal and fibrotic human liver. Am J Pathol. 144:1994;528-537.
24. Chirgwin JM, Przybyla AE, Mc Donald RJ, Rutter WJ. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry. 18:1979;5294-5299.
25. Collier IE, Wilhelm SM, Eisen AZ, Marner BL, Grant GA, Seltzer JL, Kronberger A, He C, Bauer EA, Goldberg GI. H-ras Oncogene-transformed human bronchial epithelial cells (TBE-1) secrete a single metalloprotease capable of degrading basement collagen. J Biol Chem. 263:1988;6579-6587.
26. Boone TC, Merrie JJ, De Clerck YA, Langley KE. cDNA cloning and expression of a metalloproteinase inhibitor related to tissue inhibitor of metalloproteinases. Proc Natl Acad Sci USA. 87:1990;2800-2804.
27. Ponto P, Sy N, Engel J, Gunning P, Kedes L. Evolutionary conservation in the untranslated regions of actin mRNAs: DNA sequence of a human beta-actin cDNa. Nucl Acid Res. 12:1984;1687-1696.
28. Skalli O, Ropraz P, Trzeciak A, Benzonana G, Gillessen D, Gabbiani G. A monoclonal antibody against α-smooth muscle actin: a new probe for smooth muscle differentiation. J Cell Biol. 103:1986;2787-2796.
29. Cordell JL, Falini B, Erber WN, Ghosh AK, Abdulaziz Z, MacDonald S, Pulford KAF, Stein H, Mason D. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of akaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP) complexes. J Histochem Cytochem. 32:1984;219-229.
30. Herron GS, Werb Z, Dwyer K, Banda M. Secretion of metaloproteinases by stimulated capillary endothelial cells. J Biol Chem. 261:1986;2810-2813.
31. Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E, Seiki M. A matrix metalloprotease expressed on the surface of invasive tumor cells. Nature. 370:1994;61-65.
32. Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA, Goldberg GI. Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloproteinase. J Biol Chem. 270:1995;5331-5338.
33. Arthur MJP, Friedman SL, Roll J, Bissell M. Lipocytes from normal rat liver release a neutral metalloproteinase that degrades basement membrane (type IV) collagen. J Clin Invest. 84:1989;1076-1085.
34. Grigioni WF, Garbisa S, D'Errico A, Baccarini P, Stletler-Stevenson WG, Liotta LA, Mancini AM. Evaluation of hepatocellular carcinoma aggressiveness by a panel of extracellular matrix antigens. Am J Pathol. 138:1991;647-654.
35. r72,000 type IV collagenase. Cancer Res. 52:1992;5845-5848.
36. Emmert-Buck MR, Emonard HP, Corcoran ML, Krutzsch HC, Foidart JM, Stetler-Stevenson WG. Cell surface binding of TIMP2 and pro-MMP2/TIMP2 complex. FEBS Lett. 364:1995;28-32.
37. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med. 315:1986;1650-1659.
38. Sappino AP, Schürch W, Gabbiani G. Differentiation repertoire of fibroblastic cells: expression of cytoskeletal proteins as marker of phenotypic modulations. Lab Invest. 63:1990;144-161.
39. Schmitt-Gräff A, Krüger S, Bochard F, Gabbiani G, Denk H. Modulation of alpha smooth muscle actin and desmin expression in perisinusoidal cells of normal and diseased human livers. Am J Pathol. 138:1991;1233-1242.
40. Théret N, Musso O, L'Helgoualc'h A, Clément B. Activation of matrix metalloproteinase-2 from hepatic stellate cells requires interactions with hepatocytes. Am J Pathol: in press.
41. Clément B, Levavasseur F, Loréal O, Liétard J, L'Helgoualc'h A, Guillouzo A. Role of hepatocytes and Ito cells in the synthesis and deposition of extracellular matrix. Surrenti C, Casini A, Milani S, Pinzani M. Fat-storing Cells and Liver Fibrosis. 1993;13-22 Kluwer Academic Publishers, Dordrecht.
42. Nemeth JA, Goolsby CH. TIMP2, a growth-stimulatory protein from SV40-transformed human fibroblasts. Exp Cell Res. 207:1993;376-382.
43. Murphy AN, Unsworth EJ, Stetler-Stevenson WG. Tissue inhibitor of metalloproteinases-2 inhibits bFGF-induced human microvascular endothelial cell proliferation. J Cell Physiol. 157:1993;351-358.
44. Parkins T. Researchers test TIMP-2 as a potential tumor terminator. J Natl Cancer Inst. 86:1994;174-175.
45. Kohn EC, Liotta LA. Molecular insights into cancer invasion: strategies for prevention and intervention. Cancer Res. 55:1995;1856-1862.